Rethinking biomaterials for the advancement of regenerative research & medicine

HealthX20 is a pioneering biotech company transforming the global biomaterials landscape by making research-grade materials more accessible, affordable, and abundant. By addressing critical bottlenecks in the supply of high-quality biomaterials, we empower scientists, clinicians, and innovators to accelerate discovery, improve experimental reproducibility, and translate breakthroughs into real-world medical solutions.

THE POWER OF X20

X20 Thinking questions fundamental assumptions, existing constraints, and business models entirely

X20 Requires rethinking the entire system: markets, partners, platforms, technologies, and customer behaviours

X20 Thinking demands nonlinear approaches, such as leapfrogging technologies, business model pivots, or radical cost restructuring

X20 Thinking accelerates positive global health outcomes

Our Team

  • FOUNDER & CHAIRMAN

    Anthony is the Founder CEO and Chair of Organic Technology Holdings. As an investor and entrepreneur over the past 35 years in new technologies that have the potential to have a global impact, Anthony bought a fledgling technology in 2012 and formed OTH. The technology was originally designed to work with fish waste. Quickly realizing its potential, he surrounded himself with a respected group of scientists and like-minded investors and individuals to improve and apply a series of technology improvement to treat a variety of organic waste raw materials to create valuable and in demand end products throughout the world to be used in the human food and animal feed, nutraceutical, pharmaceutical and medical research and medical device industries.

  • SENIOR RESEARCH SCIENTIST & LEAD, PHD.

    Maria Isabel Taborda Mejia is a Ph.D. in Biotechnology and a Biomedical Engineer with a strong passion for Industrial Biotechnology, technology development, and business innovation within the circular economy. She specializes in the development of sustainable biomaterials, with a focus on natural Hydroxyapatite (HAp) and Chitin derived from animal by-products. Her work bridges scientific research and industrial application, transforming biological waste into high-value products for use in medical, cosmetic, and agricultural industries. Currently, she contributes her expertise at Organic Technology Holdings, where she leads and supports key R&D initiatives. When she’s not in the lab or working on the next breakthrough, you’ll likely find her chasing sunshine on her bike, tackling a bouldering wall, or going for a refreshing run. Adventure and movement are her favorite ways to recharge

  • CHIEF SCIENTIST

    Akshat Talwalkar has a highly accomplished and uniquely diverse techno-commercial profile that includes a PhD in microbiology, 10 publications in reputed scientific journals, six commercially successful patents in grain enzyme production along with extensive on-field commercial experience of new business and market development, technical sales, process development, strategic planning and key account management across Australia and the Asia Pacific region. Akshat's industrial experience includes substantial hands-on involvement with technology start-ups and large manufacturers where he led the conceptualization and development of new technologies, set up enzyme application labs and pilot plants, worked closely with both production managers and operators to successfully scale up scientifically intricate technologies from lab to production levels and worked closely with key stakeholders of large global clients to effectively transfer the developed technologies, offering continual on-site support until they were successfully integrated and established in customers production processes.

  • CFO

    Franco Giugni is a finance professional with a chartered accounting background in taxation and extensive hands-on corporate experience across a broad range of industry sectors, focused on implementing aggressive growth strategies. Franco also leads a specialist corporate advisory firm supporting larger SMEs and small-cap ASX-listed companies with mid-market M&A requirements, as well as providing investment banking services under AFSL. Within our business, Franco plays a key role in closely overseeing the Group’s rapidly expanding local and international operations.

  • CHIEF COMMERCIAL OFFICER

    Simon Adriatico is a sales, marketing and brand professional with extensive experience across the APAC region specialising in brand development, cross border commerce and ingredient commodities trading. Having run a handful of brand and marketing agencies focussed in emerging markets, Simon has worked with several of the world’s top companies including LVMH, Volkswagen Group, IOC, Bacardi and Adidas. An early pioneer of cross border e-commerce, Simon has also developed several food & beverage and health & wellness brands in Asia and Australia. Simon is an innovator and strategic thinker with a global network encompassing a diverse range of industry sectors.

Science & Medical Advisory Board

  • Professor Meredith qualified as a dentist at Guys hospital in 1982 completing an MSc in Conservative Dentistry at the Eastman Dental Institute in London in 1988 and his first PhD at Imperial College in 1992. In 1993 he became a specialist in both Prosthodontics and Restorative dentistry.

    His research interests have focused in Biomaterials and Biomechanics. In 1992 he invented the use of Resonance Frequency Analysis to measure dental implant stability, a technique that has now become the international benchmark known as Osstell.

    He was awarded his second PhD from the University of Gothenburg for this work in 1996. Neil became Professor of Restorative Dentistry and Biomaterials at the University of Leeds in 1997.

    Following his entrepeneurial spirit he invented a dental implant system with patented biomechanics and surface technology. He raised venture capital funding and founded Neoss, of which he was CEO from 2000-2011. Neoss was in the Techtrack 100 for the fasted growing UK technology companies for three years running.

    2011 saw a return to academia when Neil joined the University of Queensland as Professor of Dental Implantology and Prosthodontics becoming the Head of Dentistry at James Cook University, Cairns, Australia in 2015. In 2020 Neil left his university ties to form the Postgraduate Institute of Dental Surgery which focusses on accredited diploma and certificate programs of excellence in dental implantology. He lectures internationally and is engaged in translational research and technology development.

  • I have been a dentist for nearly 50 years. I was one of a small percentage of female dentists at the time. In 1978 Dr Leonard Linkow, a pioneer in dental implants, offered me a place to do a clinical residency in his clinic in New York  I spent 6 months in New York studying with him in 1978. Later I was able to study under the late Dr Carl Misch, founder of the Misch International Implant Institute in USA and one of the foremost research scientists in Dental Implants, at the time. In the 1990’s I went to Portugal to do a clinical residency under Dr Palo Malo the inventor of the All-on-4 restoration for full mouth reconstruction with implants and fixed bridges. I have recently completed a Diploma of Implant Dentistry under Professor Neil Meredith, in Australia.

    These 4 men, in my opinion, are giants in the field of Dental Implants, and I have been able to use their experience, research and inventive brains to help my patients reach their goals. I have been placing implants and the related bone grafting for the past 40 years. I have also been assessing insurance claims as a medico-legal expert for over 20 years.

  • Professor Thomas Cox is a cancer cell biologist working in the field of the extracellular matrix and matrix remodelling in the progression and metastasis of solid tumours. He graduated with a Ph.D. from the University of Durham, UK in 2008, followed by PostDoctoral research positions at the Institute of Cancer Research (ICR) in London, UK and Copenhagen University, Denmark. In 2016 he was recruited to the Garvan Institute in Sydney, Australia to establish his own independent research group.

    Thomas currently leads the Matrix and Metastasis Lab, part of the Cancer Ecosystems and Translational Oncology Programs at the Garvan Institute and Kinghorn Cancer Centre. The labs creative research program integrates matrix biology with precision medicine, to make fundamental advances in personalised stromal targeting of solid tumours.